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1 In starved mice, the anorectic activity of methylamine (MET) and benzylamine (BZ), both
substrates of semicarbazide-sensitive benzylamine oxidases (Bz-SSAO), was compared with that of
the potassium channel blocking agents charybdotoxin (ChTX), tetraethylammonium (TEA),
gliquidone (GLI), ammonium chloride (NH4
+) and of the anoressants amphetamine (AMPH) and
nicotine (NIC). After i.c.v. administration, an approximate ranking order of potency was:
ChTX5AMPH4NIC=TEA5GLI5MET4BZ4NH4+.
2 Clorgyline (2.5 mg kg71 i.p.) or deprenyl (10 mg kg71 i.p.) potentiated the anorectic eect of
i.c.v.-administered BZ, NIC and AMPH. The eect of TEA was increased only by deprenyl, while
MET, NH4
+, ChTX and GLI were not aected by either of the inhibitors.
3 The Bz-SSAO inhibitors a-aminoguanidine (50 mg kg71 i.p.), B24 (100 mg kg71 i.p.) and MDL
72274 (2.5 mg kg71 i.p.) potentiated the eect of i.p., but not of i.c.v.-administered MET.
4 Antisense oligodeoxyribonucleotides (aODN) to Kv1.1 potassium channels abolished the eect of
BZ and TEA, but was ineective in reducing the activity of MET and other compounds.
5 These results suggest that MET is endowed with peculiar hypophagic eects at dosage levels that
are not able to aect gross behaviour in mice. The eect of MET, dierently from BZ, seems
unrelated to an increase in the central release of monoaminergic mediators, as well as to a Kv1.1
blocking activity. Through a reduction of the endogenous breakdown of MET, Bz-SSAO inhibitors
enhance the central pharmacological activity of this amine.
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Introduction
Methylamine (MET) is a short aliphatic amine that is
normally present in several mammals, including humans.
This compound, which can be detected in blood and urine,
may derive endogenously from the metabolism of adrenaline,
sarcosine, creatinine and lecithin. In addition, it has been
reported that MET may also derive from exogenous
compounds, such as nicotine, or be directly ingested from
food and drink (Zeisel & Dacosta, 1986). Nevertheless,
although MET has been known from many years, its
physiopathological role has still not been completely clarified.
It is known that the urinary excretion of MET is enhanced in
particular physiological conditions that are characterized by
an increase in creatine elimination, including pregnancy,
parturition and muscular exertion (Dar et al., 1985; Precious
et al., 1988). It has also been reported that the amine
increases in typhoid fever, diabetes, hepatic or renal
insuciency where it is suspected of generating a variety of
central or peripheral eects.
In the body, MET is deaminated to hydrogen peroxide
and formaldehyde by semicarbazide-sensitive benzylamine
oxidases (Bz-SSAO) (EC 1.4.3.6), a group of amine
oxidases found predominantly in the vascular tissues, fat
and connective tissue, but virtually absent in the central
nervous system. Its physiological role, moreover is not
completely understood (Lewinson et al., 1978; Buoni,
1995; Castillo et al., 1998). Tissutal Bz-SSAO, which share
the xenobiotic compound benzylamine (BZ) with MAO B
as their best substrate (Buoni, 1995), is insensitive to the
MAO (EC 1.4.3.4) inhibitors clorgyline and deprenyl but
is inhibited by semicarbazide or a-aminoguanidine (AG)
and by the highly selective inhibitors 3,5-ethoxy-4-amino-
methylpyridine (B24) (Buoni et al., 1998) or some
allylamine derivatives including (E)-2-phenyl-3-chloroallyla-
mine (MDL 72274) (Ekblom, 1998).
MET, together with Bz-SSAO, is suspected of having
possible relevance in diabetic cardiovascular degeneration
(Yu & Zuo, 1993). This view seems to be confirmed by
the observation that Bz-SSAO inhibitors have a protective
role in this pathology (Yu & Zuo, 1997), probably by
reducing the formation of the angiotoxic compound
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formaldehyde. In general, however, the inhibition of Bz-
SSAO should also be considered as a condition capable of
improving the potential biological activity of its own
substrates. This should be of particular interest in every
condition in which the formation of biologically active,
endogenous substrates of Bz-SSAO, such as MET, is
increased (Lyles & McDougall, 1989; Yu & Zuo, 1997).
Recently, this view has received some indirect experimental
support from the observation that, when administered i.p.,
BZ displays a novel central hypophagic activity in mice
only after pretreatment with the Bz-SSAO inhibitors B24
or MDL 72274. We have also observed that BZ induces
its eects probably by acting like the potassium channel
blockers TEA or 4-aminopyridine (Pirisino et al., 1993;
Banchelli et al., 2000; 2001). In other investigations, it has
been found (Ghelardini et al., 1997) that potassium
channel blockers reduce food intake in mice by acting as
depolarizing compounds in the brain. The central role of
potassium channels has been studied using aODN against
the gene that encodes the expression of delayed rectifier
K+ channels (Ik) in the cells (Hopkins & Tempel, 1992).
It has been found that repeated i.c.v. administration of
aODN, targeting the translation start region of the
mKv1.1 channel, induced hyperphagic behaviour together
with a transient specific reduction of the expression of this
channel subtype in the brain.
MET has recently been reported as blocking outward
potassium conductance (Ik) in intestinal epithelial cells
and, similarly to the anorectic compound amphetamine
(AMPH), as promoting Ca2+ dependent exocytosis in
chroman cells isolated from adrenal medulla (Mundorf
et al., 1999). Taken together, these results suggest to us
that MET, like BZ and other well-known potassium
channel blockers, may be endowed with hypophagic
activity as well. We reasoned that, if our supposition is
correct, this property could have a role, for example, in
diabetes, where high levels of circulating MET are found
and a reduction of dietary caloric intake would be
beneficial. In this hypothesis, new selective inhibitors of
Bz-SSAO would gain more attention as pharmaceutical
compounds of potential interest as enhancers of the central
eects of MET.
On the basis of these considerations, we decided to extend
to MET the investigations previously made for assessing the
hypophagic activity of BZ in mice.
In the present work we have compared the anorectic
activity of MET with that of NH4
+, TEA, GLI or ChTX,
all compounds known to block dierent types of potassium
channels (Aronson, 1992; Hrnjez et al., 1999). In addition,
the eect of NIC or AMPH, anorexic compounds that are
both generally regarded as having a mechanism of action
dierent from that of potassium channel blockers, was
evaluated. The experiments were conducted in the absence
or presence of selective AO inhibitors, in order to clarify
the potential role of Bz-SSAO inhibition in enhancing the
activity of these compounds.
In an attempt to elucidate a potassium channel blocker
activity potentially involved in the hypophagic eect of
MET, BZ and the reference compounds, we have also
planned to study the antagonism induced in mice by
pretreatment with aODN against the Kv1.1 channel
subtype.
Methods
Animals
Male Swiss albino mice (25 – 30 g) from the Morini (San Polo
d’Enza, Italy) breeding farm were used. Fifteen mice were
housed per cage. The cages were placed in the room of the
experiment 24 h before the test for adaptation. The animals
were kept at 23+18C with a 12 h light – dark cycle, light on
at 0700, and were fed a standard laboratory diet with water
ad libitum. All experiments were carried out in accordance
with the European Communities Council Directive of 24
November 1986 (86/609/EEC) for experimental animal care.
Intracerebroventricular injection technique
Intracerebroventricular (i.c.v.) administration was performed
under ether anaesthesia, according to the method described
by Haley & McCormick (1957). Briefly, under anaesthesia,
the mice were grasped firmly by the loose skin behind the
head. A 0.4 mm external diameter, hypodermic needle
attached to a 10 micro syringe was inserted perpendicularly
through the skull, no more than 2 mm into the brain of the
mouse, where 5 ml were then administered. The injection site
was 1 mm to the right or left from the midpoint, on a line
drawn through to the anterior base of the ears. Injections
were performed randomly into the right or left ventricle. To
make sure that the drugs had been administered exactly into
the cerebral ventricle, some mice were injected with 5 ml of
1 : 10 diluted India ink and their brains were examined
macroscopically after sectioning. When i.c.v. administration
was used, it was previously assessed that the pH values of the
nM compound solutions, ranging from 7.2 to 6.7, did not
vary significantly from that of the saline (pH=6.8+0.4).
Evaluation of food consumption
The mice did not have access to food for 12 h, but water was
available ad libitum. A weighed amount of food (standard
laboratory pellets) was given, and the weight consumed
(evaluated as the dierence between the original amount and
the food left in the cage, including spillage) was measured 15,
30, 45 and 60 min after i.c.v. or i.p. administration of saline
or drug solutions, with an accuracy of 0.1 g. An arbitrary
cut-o time of 60 min was used. To obtain selective
inhibition of monoamine oxidase A and B activities in mouse
brain, we administered 2.5 mg kg71 i.p. clorgyline or
10 mg kg71 deprenyl (Finnegan et al., 1995). With regard
to the dosage regimen of MDL 72274, B24 or AG as
inhibitors of semicarbazide-sensitive benzylamine oxidases,
the same dosage (2.5 mg kg71 i.p.; 100 mg kg71; 50 mg kg71
respectively) previously found to be eective for these
enzymes (Yu & Zuo, 1997; Banchelli et al., 2001) was given
i.p. to the mice. Each inhibitor was administered i.p. to the
mice 3 h before the injection (i.c.v. or i.p.) of either saline or
test compounds.
Antisense oligonucleotides
24mer phosphodiester oligonucleotides (ODNs) were capped
by a terminal phosphorothioate double substitution and
purified by high-performance liquid chromatography (HPLC;
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Genosys, The Woodlands, TX, U.S.A.). The antisense
oligonucleotide (5’-CGA CAT CAC CGT CAT GAT GAA
AGG-3’) was designed by targeting the 5’ portion of the
murine Kv1.1 mRNA, residues 575 – 598 of the published
cDNA sequence (Chandy et al., 1990). To evaluate the
specific, antisense eects of the oligodeoxynucleotides, a fully
degenerated phosphorodiester phosphorothioate-capped
oligonucleotide was used as negative control. The fully
degenerated 24mer is a collection of about 361014 dierent
molecular species. Therefore, for the nanomolar-micromolar
range concentrations obtained in antisense experiments, every
oligonucleotide of a defined sequence was present at the site
of action in a sub-attomolar concentration, which is totally
insucient for any antisense eect. For more details on the
aODN and dODN synthesis and the RT–PCR analysis of
mKv1.1 mRNA in the mouse brain tissue the reader may
refer to our previous papers (Ghelardini et al., 1997; Galeotti
et al., 1997).
Administration of antisense oligonucleotide
In experiments in vivo, to favour cell penetration and to
minimize the degradation of the oligonucleotides, phosphor-
othioate-capped phosphorodiester oligonucleotides associated
with an artificial cationic lipid (DOTAP) to enhance cellular
uptake, has been proved to be suitable (Quattrone et al.,
1994). Mice were randomly assigned to an antisense
oligonucleotide (aODN), degenerated oligonucleotide
(dODN), vector (DOTAP; N-[1-(2,3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium methyl sulphate), saline or naı¨ve
group. A suitable amount of oligonucleotide was preincub-
ated at 378C for 30 min with 13 mM DOTAP. Each group
received a single intracerebroventricular (i.c.v.) injection (5 ml;
3 nmol of ODN) on days 1, 4 and 7.
Rota rod test
The apparatus consisted of a base platform and a rotating
rod with a diameter of 3 cm and non-skid surface. The rod
was placed at a height of 15 cm from the base. The rod,
30 cm in length, was divided into five equal sections by six
disks. Up to five mice were then tested simultaneously on the
apparatus, with a rod rotation speed of 16 r.p.m. The
integrity of motor coordination was assessed on the basis
of the number of falls from the rod in 30 s. Performance time
was measured before and 15, 30, 45 and 60 min after the
i.c.v. administration of saline or drug solutions.
Reagents and drugs
Oligonucleotides used for the antisense strategy were from
Genosys (The Woodlands, U.S.A.). DOTAP was from
Boheringer-Mannheim (Mannheim, Germany). Deprenyl
hydrochloride, clorgyline hydrochloride, benzylamine hydro-
chloride, methylamine hydrochloride, amphetamine sulphate,
tetraethylammonium HCl, charybdotoxin, nicotine and
gliquidone were purchased from the Sigma Chemical
Company (St. Louis, MO, U.S.A.). MDL 72274 was a gift
of the Marion Merrell Dow Research Institute (Strasbourg
Cedex, France). B24 was synthesized by Prof V. Bertini
(Department of Organic Chemistry of the University of
Genoa).
The drugs were dissolved in isotonic (NaCl 0.9%) saline
solution; drug concentrations were prepared in such a way
that the necessary dose could be administered in a volume of
5 ml/mouse by i.c.v. injection and 10 ml kg71 by i.p. injection.
Antisense and degenerated oligonucleotides were dissolved in
the vector (DOTAP) at least 30 min before injection.
Statistical analysis
All experimental results are expressed as the mean+s.e.mean.
Analysis of variance (ANOVA), followed by Fisher’s
Protected Least Significant Dierence (PLSD) procedure for
post hoc comparison, were used to verify significance between
two means. Data were analysed using the StatView software
for Machintosh (1992). The fitting of the sigmoid dose-
response curves and the ED50 values with their confidence
limits (C.L.), were obtained from a non-linear regression
analysis (Prism program, Graph Pad Software Inc., San
Diego, CA, U.S.A.).
Results
Food intake behaviour
In the mice starved for 12 h, 15 mg MET given i.c.v.
significantly reduced food consumption, as compared to the
controls in a 60 min test. At this dosage (Table 1), MET was
more active, as a hypophagic compound, than BZ (30 mg),
NH4
+ (12 mg), TEA (5 mg), ChTX (1 mg), GLI (6 mg) or NIC
(5 mg) were. From the dose-response relationship (Figure 1) an
ED50 value was calculated of 146.3 nmol/mouse (CL=36.2 –
591.1) and 63.2 nmol/mouse (CL=13.7 – 262.9), for BZ and
MET, respectively. The i.p. pretreatment of mice with clorgy-
line (2.5 mg kg71) or deprenyl (10 mg kg71) to selectively
inhibit MAOA orMAO B activities (Banchelli et al., 2001), did
not aect the basal food consumption of the controls, but
dierently modified the anorectic eect of some i.c.v.-
administered compounds. Namely, the anorectic eect of BZ,
AMPH andNIC was potentiated by clorgyline (40, 67 and 18%
respectively) and deprenyl (64, 88 and 27% respectively), the
eect of TEA only by deprenyl (64%), while the activity of
MET, ChTX, GLI remained completely unmodified after
selective MAOs inhibition (Table 1). After the i.p. pretreatment
with MDL 72274, the anorectic eect of MET given i.c.v. was
unmodified; on the contrary, this inhibitor significantly
potentiated the hypophagic eect of MET when this compound
was administered i.p. (Figure 2). The EC50 values for MET
were reduced from 334.6 mg kg71 (CL=280.8 – 398.8) to
43.05 mg kg71 (CL=38.51 – 48.13) in controls and MDL
72274 pretreated mice, respectively. Similar results (Figure 2)
were also obtained when the Bz-SSAO inhibitors B24
(100 mg kg71) or AG (50 mg kg71) was given i.p. to mice;
again, the EC50 values for MET were reduced approximately to
45.72 mg kg71 and 37.68 mg kg71 respectively.
Effect of aODN to mKv1.1 pretreatments
The eect induced by repeated administration of aODN
against mKv1.1 on the anorectic activity of MET compared
to those of BZ and other reference compounds was investigated
in food-deprived mice. The experiments were performed 48 h
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after the last aODN administration, because at this time a
substantial reduction (470%) in Kv1.1 mRNA levels was
previously obtained in brain homogenates, which returned to
control levels only after 7 days (Ghelardini et al., 1997)
In our experiments, the i.c.v. injection of 3 nmol of aODN
as well as of dODN, as negative controls, did not modify
food intake in comparison with the vehicle-treated mice. On
the contrary, the aODN decreased the hypophagic eect
induced by BZ and TEA or AMPH, while the same
treatment did not aect the anorectic activity of MET,
NH4
+, NIC, ChTX or GLI (Table 2). The hypothesis that
the aODN pretreatment eectively decreased the hypophagic
eect of some compounds through a reduction in the Kv1.1
channel expression was further confirmed by the recovery of
the anorectic eect of 5 mg TEA administered 7 days after the
last of aODN pretreatment (food consumption=674+25 mg
per mouse after 48 h, in comparison with 365+18 mg per
mouse after 7 days of aODN pretreatment; P50.01, n=10).
It has been previously seen, in fact, that, after 7 days, the
inhibitory eect of aODN on Kv1.1 mRNA levels completely
disappeared in the brain of the treated mice (Ghelardini et
al., 1997).
Effect of treatments on mouse behaviour
The motor coordination in mice after dierent pharmacologi-
cal treatments was evaluated by the rota-rod test starting
15 min after the i.c.v. injection of the test compounds or 48 h
after the last ODN injection. As shown in Table 3, with the
exclusion of AMPH, the motor coordination of the mice
treated with the highest dosage of compounds used in food
intake experiments was not modified. In comparison with the
control mice, the treated animals reduced the number of falls
during observation to a similar extent indicating that they
learned how to balance on the rotating rod in a similar
manner.
Discussion
We compared the central hypophagic eect of MET, an
endogenous substrate of Bz-SSAO, to that of BZ, a synthetic
amine deaminated by both Bz-SSAO and MAO B enzymes.
Table 1 Anorectic eect of MET, BZ and other treatments in mice food-deprived for 12-h
Food consumption mg/mouse
Compounds Saline Clorgyline Deprenyl MDL 72274
i.c.v. (10 ml kg71 i.p.) (2.5 mgkg71 i.p.) (10 mgkg71 i.p.) (2.5 mgkg71 i.p.)
Saline 5 ml 677+14 626+31 575+26 670+40
MET 15 mg 166+20 153+28 179+21 196+25
AMPH 2 mg 247+14 82+16* 31+7.5* N.T.
BZ 33 mg 265+32 160+31* 95+16* 295+23
NH4
+ 12 mg 438+31 492+24 439+18 N.T.
TEA 5 mg 320+21 315+22 115+34* N.T.
ChTX 1 mg 269+18 218+17 241+34 N.T.
GLI 6 mg 340+25 363+20 322+16 N.T.
NIC 5 mg 310+16 254+26* 228+22* 379+17
All tested compounds significantly reduced food intake in mice (P50.01) in comparison with the respective controls (saline injected).
Each value represents the mean+s.e.mean of 10 – 40 animals. *Significant (P50.01) in comparison with the anorectic eect of the
compound in saline pretreated animals. N.T. not tested.
Figure 1 Dose-food consumption curves of i.c.v. injected MET, in
mice food-deprived for 12-h, as compared to the anorectic eect of
BZ. Each point represents the mean+s.e.mean for 10 – 20 mice.
Figure 2 Shift to the left of the dose-food consumption curves of
i.p.-injected MET, in mice food-deprived for 12-h by the inhibition of
semicarbazide-sensitive benzylamine oxidases (B24 100 mg kg71;
MDL 72274 2.5 mg kg71; AG 50 mg kg71). Mice were injected i.p.
with saline or MET solution 15 min before the test. Amine oxidase
inhibitors were administered 60 min before treatment with MET.
Each point represents the mean+s.e.mean for 10 – 20 mice.
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It was found that MET induced anorectic eects in mice at
lower dosages than those of BZ.
One of the main purposes of this work was to verify the
influence of the selective inhibition of MAO A, MAO B and
Bz-SSAO, respectively on the pharmacological activity of
MET compared to that of BZ and other reference
compounds, after clorgyline, deprenyl and MDL 72274 mice
pretreatments. To this aim we used the same dosage schedule
of the inhibitors previously reported to induce a selective and
statistically significant (more than 85%) inhibition of the
appropriate AO subtype in the tissues of the mice (Banchelli
et al., 2001). Depending on the absence of Bz-SSAO in the
brain, the eect of MET, injected directly into cerebral
ventricles, was unaected by pretreatments with MDL 72274,
a selective and irreversible inhibitor of these enzymes.
Clorgyline or deprenyl were also without eect in modifying
the hypophagic activity of MET, while they significantly
potentiated the anorexia induced by BZ, TEA or AMPH.
As reported previously in more detail (Banchelli et al.,
2001), the observation that the hypophagic eect of BZ is
potentiated by both MAO A and MAO B inhibitors has been
explained by the inhibition of the deamination of 5HT (MAO
A substrate) or DA (MAO B substrate) probably released by
BZ in the brain. Furthermore the selective inhibition of MAO
B may eectively increase the levels of unchanged BZ active
in the brain.
It is known that NIC, TEA or AMPH can reduce food
intake in animals by stimulating, with dierent mechanisms,
the neuronal release of either 5HT or DA (Parada et al.,
1988; Dawson & Routledge, 1995; Miyata et al., 1999). The
observation that the hypophagic eect of these compounds,
which are not MAOs substrates, was potentiated by the
inhibition of these enzymes can only be explained as a
reduction in the oxidative deamination of monoaminergic
mediators released by these compounds.
A number of novel mediators have been identified in the
central regulation of feeding including, for example,
peptidergic compounds like NPY, CCK, CRF, etc (Inui,
2000). Because both clorgyline and deprenyl were without
eect in potentiating the hypophagic activity of MET, NH4
+,
ChTX or GLI, it is possible that, at the dosages employed
and dierently from AMPH, BZ or TEA, these compounds
might preferentially influence the release of some anorectic,
non monoaminergic mediators, the nature of which warrants
further investigations.
In contrast to the results obtained in i.c.v. experiments, the
selective inhibition of Bz-SSAO potentiated the hypophagic
eect of MET given i.p. to mice. Once more, this feature
seems very similar to the one previously observed with BZ
(Banchelli et al., 2001) and confirms that Bz-SSAO could be
regarded as scavenger enzymes capable of protecting the
central nervous system from the permeation of some centrally
active amines.
It is known that circulating MET increases in dierent
types of diabetes, together with the activity of vascular Bz-
SSAO (Boor et al., 1992; Meszaros et al., 1999) which oxidize
them into formaldehyde and H2O2. There has been
considerable debate about the physiopathological significance
of these observations. Because formaldehyde is an angiotoxic
compound, the high levels of both MET and Bz-SSAO may
have a role in the cardiovascular degeneration observed in
diabetes, and may contribute to explaining the favourable
eects of Bz-SSAO inhibitors in this pathology (Lyles &
McDougall, 1989; Hammes et al., 1994; Yu & Zuo, 1997;
Ekblom, 1998). Moreover, in considering the hypophagic
eect of MET, it can also be hypothesized that the increased
levels of this aliphatic amine in diabetes represent a part of
the physiological mechanisms involved in the control of
hyperglycaemia. Thus, notwithstanding the fact that a
hypophagic eect after chronic Bz-SSAO inhibition has not
yet been reported, our results could suggest that, through an
increase in circulating MET, Bz-SSAO inhibitors, could be
useful in diabetes by reducing food consumption and caloric
intake. This could be particularly true in insulin-independent
diabetes mellitus, a dismetabolic condition that is often
associated with obesity, in which increases of both MET
levels and Bz-SSAO activity have been observed (Ekblom,
1998).
More than sixty potassium channel subunits have been
cloned to date. According to currently accepted nomencla-
ture, the acronym KvX.Y defines a population of voltage-
activated channels which are structurally dierent, for
example, to ligand gated (KirX.Y) or Ca2+-operated (mlso)
ones (Snyders, 1999).
Table 2 Eect of the aODN pretreatment on the anorexia
induced by MET, BZ and other treatments
Food consumption mg/mouse
Compounds dODN aODN % over
i.c.v. 3 nmol i.c.v. 3 nmol i.c.v. control
Saline 15 ml 653+26 697+20 +6.7
MET 15 mg 154+21 131+27 714.9
AMPH 2 mg 238+31 569+22* +139.1
BZ 33 mg 261+27 523+19* +100.4
NH4
+ 12 mg 449+23 429+25 74.4
TEA 5 mg 381+16 647+25* +76.9
ChTX 1 mg 228+36 251+32 +10.1
GLI 6 mg 346+23 360+18 +4.0
NIC 5 mg 281+20 305+14 +8.5
All tested compounds significantly reduced food intake in
mice (P50.01) in comparison with the respective aODN or
dODN pretreated, saline injected, controls. Each value
represents the mean+s.e.mean (n=10). *Significant
(P50.01) in comparison with the anorectic eect of the
compound in dODN pretreated animals.
Table 3 Eect of MET, BZ and other compounds in the
mouse rota-rod test
Number of falls in 30 seconds
Before After treatment
Compounds treatment 15 min 30 min 45 min
Saline 5 ml i.c.v. 3.1+0.3 1.8+0.3 1.4+0.3 0.8+0.2
BZ 33 mg i.c.v. 2.9+0.3 1.7+0.3 1.1+0.5 1.1+0.5
MET 15 mg i.c.v. 3.1+0.3 2.4+0.6 2.0+0.4 1.7+0.2
MET 600 mgkg71 i.p. 3.2+0.4 2.7+0.3 1.5+0.3 1.2+0.2
AMPH 2 mg i.c.v. 2.4+0.3 3.1+0.3* 3.3+0.4* 2.7+0.4*
TEA 5 mg i.c.v. 3.2+0.4 2.1+0.3 1.3+0.4 1.2+0.4
NIC 5 mg i.c.v. 3.7+0.5 2.6+0.4 1.7+0.3 0.9+0.2
ChTX 1 mg i.c.v. 3.3+0.4 1.9+0.5 1.6+0.3 1.1+0.3
GLI 6 mg i.c.v. 3.5+0.3 2.5+0.4 1.6+0.3 1.1+0.2
aODN 3 nmol i.c.v. 3.2+0.4 2.0+0.4 1.8+0.4 1.0+0.3
dODN 3 nmol i.c.v. 3.6+0.3 2.6+0.5 1.9+0.3 0.6+0.2
Each value represents the mean+s.e.mean of 8 – 10 mice.
*P50.01 in comparison with saline-treated controls.
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It is known that TEA blocks dierent types of potassium
channels in neurons, including voltage- and calcium-activated
ones (Halliwell, 1990). On the other hand, ChTX has been
reported to block currents through the calcium activated
potassium channels, while sulphonylureas, such as gliqui-
done, block KATP channels in dierent cells, including
neurons (Cook, 1988; Edwards & Weston, 1993).
We reported that i.c.v. injections of K+ channel blockers
induced a decrease in food consumption in mice, whereas the
openers did the opposite. The observation that aODN, which
inhibited the expression in the C.N.S. of Shaker-like Kv1.1
potassium channels, also showed orexic properties in starved
mice, further indicate a role of these voltage-activated
channels in the physiological control of food intake
(Ghelardini et al., 1997).
We investigated the possible potassium channel blocking
eect of BZ, MET and other hypophagic compounds in mice,
using an antisense strategy. The aODN specifically bind to
targeted mRNA, preventing translation and/or mediating
mRNA cleavage by Rnase and thus down-regulating the
synthesis of the encoded protein. The aODN was used
assuming that a reduction in the expression of Kv1.1
potassium channels would decrease the pharmacological
activity of compounds believed to interact with this molecular
target. This strategy has proved to be successful, for example,
in studies on the role of potassium channels in the central
activity of dierent analgesic drugs (Chen et al., 1995;
Galeotti et al., 1997).
The administration schedule of aODN (a single i.c.v.
injection on days 1, 4 and 7 before the administration of
compounds) was chosen on the basis of previous results with
quantitative RT –PCR analysis that showed that this
treatment significantly reduced the expression of Kv1.1
channels in mouse brain (Galeotti et al., 1997). In this
regard, it must be mentioned that this aODN pretreatment
was unable to further increase food consumption in the
animals, which was maximally stimulated after 12 h of
fasting.
In our experiments, the anorectic eect of TEA was
completely antagonized by aODN. The antagonism was also
present for BZ, supporting our previous observation on its
action mechanism and further indicating that, similarly TEA
and at the dosage used, the eect of these compounds was
probably due to a block of the Kv1.1 channel subtype.
It was shown that NH4
+, as well as MET, could modify
the exocitotic process by blocking potassium channels of
dierent types (Hrnjez et al., 1999) and because of their
elevated circulating levels, may be contributory neurodepres-
sant compounds in cirrhotic and uremic patients (Simeno,
1975; Butterworth, 1992).
Dierently from TEA or BZ, the hypophagic eect of
NH4
+ and MET was not antagonized by the pretreatment
with the aODN to mKv1.1 subtype. Therefore, it is possible
to hypothesize that both NH4
+ and MET induce their
hypophagic eect probably by blocking voltage dependent
channels dierent to Kv1.1.
A generally accepted action mechanism for AMPH and for
several related psychostimulants proposes that these amines
increase intersynaptic catecholamine levels indirectly, acting
on vesicular transporters. It has recently been found that
AMPH release neuromediators also by increasing the
intragranular pH in neurons, thus disrupting the association
of catecholamines with Ca2+, ATP and vesicular proteins
(Mundorf et al., 1999). We now observed that the aODN
pretreatment almost completely prevented the hypophagic
eect of AMPH; considering that no previous observations
on a possible potassium channel blocking activity of AMPH
have yet been reported, these results were unexpected.
However, the observation that dexfenfluramine, an anorectic
compound structurally related to AMPH and known to be a
serotoninergic releasing agent, may act by blocking delayed
rectifier K+ channels (Hu et al., 1998) might indirectly
support a similar activity of AMPH.
In our opinion, these results are interesting in the view of
an alternative mechanism of action of AMPH and
structurally related drugs. Moreover, our results suggest that
aODN against Kv1.1 potassium channels could be useful
tools for investigating the relationship between channel
modulation and other behavioural properties of AMPH,
such as, for example, central excitation, motor stimulation or
memory improvement.
To conclude, in the present work we have demonstrated
that MET is endowed with peculiar hypophagic eects at
dosage levels that are unable to aect motility and gross
behaviour in mice. Indirect evidence indicates that, dierently
from BZ, the anorectic eect of MET is probably related
neither to an increase in the central release of monoaminergic
mediators or to a Kv1.1 channel blocking activity. This eect
is potently increased by selective Bz-SSAO inhibitors,
indicating that, through a reduction in the endogenous
breakdown of MET, these agents may improve the central
physiopharmacological activity of this amine.
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